Related Experiment Video
Updated: Feb 12, 2026
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Evidence-based Management of Cardiogenic Shock After Acute Myocardial Infarction
Karl Werdan1, Martin Russ2, Michael Buerke3
1Halle(Saale).
Insights
Early revascularization is key for cardiogenic shock post-myocardial infarction. However, the Intra-aortic Balloon Pump in Cardiogenic Shock II trial found that IABP therapy does not improve mortality rates.
Area of Science:
- Cardiology
- Intensive Care Medicine
- Evidence-Based Medicine
Background:
- Cardiogenic shock following acute myocardial infarction (AMI) requires prompt management, focusing on revascularization and organ support.
- Effective treatment of complications like acute respiratory failure and multiple organ dysfunction syndrome (MODS) is crucial.
- Intensive care is vital for critically ill patients with high mortality.
Purpose of the Study:
- To review evidence-based guidelines for managing cardiogenic shock post-AMI.
- To evaluate the role of adjunctive Intra-aortic Balloon Pump (IABP) therapy in this patient population.
Main Methods:
- Analysis of current guidelines for cardiogenic shock management.
- Inclusion of data from the Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP SHOCK II) trial.
Main Results:
- Early revascularization of the occluded coronary artery is a Class I recommendation with high evidence.
- Most other guideline recommendations have low evidence levels, often based on expert opinion.
- The IABP SHOCK II trial demonstrated that adjunctive IABP therapy does not reduce 30-day or six-month mortality.
Conclusions:
- While early revascularization is paramount, the benefit of IABP therapy in cardiogenic shock post-AMI is not supported by recent trial data.
- Future guidelines may need revision regarding IABP use, emphasizing the need for high-level evidence for interventions.
Abstract:
Guidelines for evidence-based management of patients with cardiogenic shock after acute myocardial infarction focuses on early revascularisation of the occluded coronary artery as well as on support of cardiac failure and improvement of impaired organ perfusion. Also of great importance is effective treatment of shock complications, especially acute respiratory failure and other forms of multiple organ dysfunction syndrome (MODS). Cardiovascular therapy has to be accompanied by best general intensive care of these critically ill patients with high mortality. Most lives can be saved by early revascularisation, and this class I recommendation has a high level of evidence. So far, most of the other guideline recommendations are of low evidence level, in most cases based on expert opinions. Recently, the Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP SHOCK II) trial with 600 patients has shown that adjunctive IABP therapy - for long a class I recommendation - does not reduce 30-day and six-month motality.
Related Concept Videos
02:55The Evidence for Evolution
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:26Acute Coronary Syndrome V: Nursing Management
01:22Acute Kidney Injury VI: Nursing Management
01:16Shock Waves
When the source's speed approaches the speed of sound, constructive interference between successive wavefronts emitted by the source occurs immediately behind it. Initially, scientists believed that this constructive interference would result in such high...